Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee

被引:14
作者
Nicely, Nathan I. [1 ]
Wiehe, Kevin [1 ]
Kepler, Thomas B. [2 ]
Jaeger, Frederick H. [1 ]
Dennison, S. Moses [1 ]
Rerks-Ngarm, Supachai [3 ]
Nitayaphan, Sorachai [4 ]
Pitisuttithum, Punnee [5 ]
Kaewkungwal, Jaranit [5 ]
Robb, Merlin L. [6 ]
O'Connell, Robert J. [4 ]
Michael, Nelson L. [7 ]
Kim, Jerome H. [7 ]
Liao, Hua-Xin [1 ]
Alam, S. Munir [1 ]
Hwang, Kwan-Ki [1 ]
Bonsignori, Mattia [1 ]
Haynes, Barton F. [1 ]
机构
[1] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27708 USA
[2] Boston Univ, Dept Microbiol, Boston, MA 02215 USA
[3] Minist Publ Hlth, Nonthaburi, Thailand
[4] Armed Forces Res Inst Med Sci, Bangkok, Thailand
[5] Mahidol Univ, Bangkok 10700, Thailand
[6] US Mil HIV Res Program, Henry Jackson Fdn HIV Program, Bethesda, MD USA
[7] Walter Reed Army Inst Res, US Mil HIV Res Program MHRP, Silver Spring, MD USA
来源
EBIOMEDICINE | 2015年 / 2卷 / 07期
关键词
HIV-1; Gp120; V2; RV-144; Antibody maturation; Germline; Unmutated ancestor; NEUTRALIZING ANTIBODIES; AFFINITY MATURATION; INTEGRIN ALPHA(4)BETA(7); CRYSTAL-STRUCTURE; IMMUNE-RESPONSE; BROAD; RECOGNITION; EVOLUTION; BINDING; FLEXIBILITY;
D O I
10.1016/j.ebiom.2015.06.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Human monoclonal antibody CH58 isolated from an RV144 vaccinee binds at Lys169 of the HIV-1 Env gp120 V2 region, a site of vaccine-induced immune pressure. CH58 neutralizes HIV-1 CRF_ 01 AE strain 92TH023 and mediates ADCC against CD4+T cell targets infected with CRF_ 01 AE tier 2 virus. CH58 and other antibodies that bind to a gp120 V2 epitope have a second light chain complementarity determining region (LCDR2) bearing a glutamic acid, aspartic acid (ED) motif involved in forming salt bridges with polar, basic side amino acid side chains in V2. In an effort to learn how V2 responses develop, we determined the crystal structures of the CH58-UA antibody unliganded and bound to V2 peptide. The structures showed an LCDR2 structurally preconformed from germline to interact with V2 residue Lys169. LCDR3 was subject to conformational selection through the affinity maturation process. Kinetic analyses demonstrate that only a few contacts were responsible for a 2000-fold increase in KD through maturation, and this effect was predominantly due to an improvement in off-rate. This study shows that preconformation and preconfiguration can work in concert to produce antibodies with desired immunogenic properties. (C) 2015 The Authors. Published by Elsevier B. V.
引用
收藏
页码:713 / 722
页数:10
相关论文
共 4 条
  • [1] Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
    Edlefsen, Paul T.
    Rolland, Morgane
    Hertz, Tomer
    Tovanabutra, Sodsai
    Gartland, Andrew J.
    decamp, Allan C.
    Magaret, Craig A.
    Ahmed, Hasan
    Gottardo, Raphael
    Juraska, Michal
    McCoy, Connor
    Larsen, Brendan B.
    Sanders-Buell, Eric
    Carrico, Chris
    Menis, Sergey
    Bose, Meera
    Arroyo, Miguel A.
    O'Connell, Robert J.
    Nitayaphan, Sorachai
    Pitisuttithum, Punnee
    Kaewkungwal, Jaranit
    Rerks-Ngarm, Supachai
    Robb, Merlin L.
    Kirys, Tatsiana
    Georgiev, Ivelin S.
    Kwong, Peter D.
    Scheffler, Konrad
    Pond, Sergei L. Kosakovsky
    Carlson, Jonathan M.
    Michael, Nelson L.
    Schief, William R.
    Mullins, James I.
    Kim, Jerome H.
    Gilbert, Peter B.
    PLOS COMPUTATIONAL BIOLOGY, 2015, 11 (02)
  • [2] Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
    Gottardo, Raphael
    Bailer, Robert T.
    Korber, Bette T.
    Gnanakaran, S.
    Phillips, Joshua
    Shen, Xiaoying
    Tomaras, Georgia D.
    Turk, Ellen
    Imholte, Gregory
    Eckler, Larry
    Wenschuh, Holger
    Zerweck, Johannes
    Greene, Kelli
    Gao, Hongmei
    Berman, Phillip W.
    Francis, Donald
    Sinangil, Faruk
    Lee, Carter
    Nitayaphan, Sorachai
    Rerks-Ngarm, Supachai
    Kaewkungwal, Jaranit
    Pitisuttithum, Punnee
    Tartaglia, James
    Robb, Merlin L.
    Michael, Nelson L.
    Kim, Jerome H.
    Zolla-Pazner, Susan
    Haynes, Barton F.
    Mascola, John R.
    Self, Steve
    Gilbert, Peter
    Montefiori, David C.
    PLOS ONE, 2013, 8 (09):
  • [3] HLA class II diversity in HIV-1 uninfected individuals from the placebo arm of the RV144 Thai vaccine efficacy trial
    Baldwin, K. M.
    Ehrenberg, P. K.
    Geretz, A.
    Prentice, H. A.
    Nitayaphan, S.
    Rerks-Ngarm, S.
    Kaewkungwal, J.
    Pitisuttithum, P.
    O'Connell, R. J.
    Kim, J. H.
    Thomas, R.
    TISSUE ANTIGENS, 2015, 85 (02): : 117 - 126
  • [4] Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
    Moodie, Zoe
    Dintwe, One
    Sawant, Sheetal
    Grove, Doug
    Huang, Yunda
    Janes, Holly
    Heptinstall, Jack
    Omar, Faatima Laher
    Cohen, Kristen
    De Rosa, Stephen C.
    Zhang, Lu
    Yates, Nicole L.
    Sarzotti-Kelsoe, Marcella
    Seaton, Kelly E.
    Laher, Fatima
    Bekker, Linda-Gail
    Malahleha, Mookho
    Innes, Craig
    Kassim, Sheetal
    Naicker, Nivashnee
    Govender, Vaneshree
    Sebe, Modulakgotla
    Singh, Nishanta
    Kotze, Philip
    Lazarus, Erica
    Nchabeleng, Maphoshane
    Ward, Amy M.
    Brumskine, William
    Dubula, Thozama
    Randhawa, April K.
    Grunenberg, Nicole
    Hural, John
    Kee, Jia Jin
    Benkeser, David
    Jin, Yutong
    Carpp, Lindsay N.
    Allen, Mary
    D'Souza, Patricia
    Tartaglia, James
    DiazGranados, Carlos A.
    Koutsoukos, Marguerite
    Gilbert, Peter B.
    Kublin, James G.
    Corey, Lawrence
    Andersen-Nissen, Erica
    Gray, Glenda E.
    Tomaras, Georgia D.
    McElrath, M. Juliana
    JOURNAL OF INFECTIOUS DISEASES, 2022, 226 (02) : 246 - 257